Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rabbit Anti-human T-lymphocyte Globulin
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Fosun Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Neovii and Fosun Pharma Enter Into an Exclusive Agreement
Details : Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® (Rabbit Anti-human T-lymphocyte Globulin) to Fosun Pharma Industry.
Product Name : Grafalon
Product Type : Protein
Upfront Cash : Undisclosed
July 09, 2022
Lead Product(s) : Rabbit Anti-human T-lymphocyte Globulin
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Fosun Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Tel Aviv University
Deal Size : Undisclosed
Deal Type : Collaboration
TAU and Neovii Team Up to Develop Covid-19 Vaccine
Details : The deal provides Neovii with the exclusive right to develop and commercialise a platform technology created by Biotechnology professor Jonathan Gershoni of TAU’s School of Molecular Cell Biology, to rapidly identify epitope-based vaccines.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Tel Aviv University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EE-TP
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Recipient : St George's, University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 07, 2019
Lead Product(s) : EE-TP
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Recipient : St George's, University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 05, 2012
Lead Product(s) : Atg-Fresenius S
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Eurotrials Brasil | Recerca Clínica | PsyConsult
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 29, 2011
Lead Product(s) : Atg-Fresenius S
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Eurotrials Brasil | Recerca Clínica | PsyConsult
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 22, 2011
Lead Product(s) : US-ATG-F
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2011
Lead Product(s) : US-ATG-F
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 23, 2010
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 09, 2010
Reset All
